Table 3.
Performance metrics of the four candidate blood transcriptional signatures with the highest diagnostic accuracy
| Sensitivity | Specificity | PPV | NPV | |
|---|---|---|---|---|
| At maximum Youden index | ||||
| BATF2 | 87·0% (75·6–93·6) | 79·5% (71·7–85·6) | 64·4% (52·9–74·4) | 93·5% (87·2–96·8) |
| Kaforou25 | 74·1% (61·1–83·9) | 89·8% (83·3–93·9) | 75·5% (62·4–85·1) | 89·1% (82·5–93·4) |
| Roe3 | 90·7% (80·1–96·0) | 74·0% (65·8–80·9) | 59·8% (48·9–69·7) | 94·9% (88·7–97·8) |
| Sweeney3 | 87·0% (75·6–93·6) | 85·0% (77·8–90·2) | 71·2% (59·4–80·7) | 93·9% (88·0–97·0) |
| At minimum sensitivity for a triage test | ||||
| BATF2 | 90% | 59·8% (51·1–68·0) | 48·8% (39·2–58·5) | 93·4% (85·8–97·0) |
| Kaforou25 | .. | 62·2% (53·5–70·2) | 50·3% (40·5–60·1) | 93·6% (86·3–97·2) |
| Roe3 | .. | 74·0% (65·8–80·9) | 59·6% (48·7–69·5) | 94·6% (88·2–97·6) |
| Sweeney3 | .. | 75·6% (67·4–82·2) | 61·1% (50·1–71·0) | 94·7% (88·5–97·6) |
| At minimum specificity for a triage test | ||||
| BATF2 | 88·9% (77·8–94·8) | 70% | 55·7% (45·2–65·8) | 93·7% (86·9–97·1) |
| Kaforou25 | 83·3% (71·3–91·0) | .. | 54·2% (43·5–64·4) | 90·8% (83·4–95·1) |
| Roe3 | 90·7% (80·1–96·0) | .. | 56·3% (45·8–66·2) | 94·7% (88·1–97·7) |
| Sweeney3 | 90·7% (80·1–96·0) | .. | 56·3% (45·8–66·2) | 94·7% (88·1–97·7) |
| At optimum sensitivity for a triage test | ||||
| BATF2 | 95% | 25·2% (18·5–33·4) | 35·1% (27·8–43·1) | 92·2% (78·6–97·5) |
| Kaforou25 | .. | 28·3% (21·2–36·7) | 36·1% (28·6–44·2) | 93·0% (80·6–97·7) |
| Roe3 | .. | 13·4% (8·5–20·4) | 31·8% (25·1–39·3) | 86·3% (65·3–95·5) |
| Sweeney3 | .. | 54·3% (45·7–62·7) | 46·9% (37·8–56·2) | 96·2% (89·0–98·8) |
| At optimum specificity for a triage test | ||||
| BATF2 | 85·2% (73·4–92·3) | 80% | 64·4% (52·8–74·5) | 92·7% (86·3–96·3) |
| Kaforou25 | 81·5% (69·2–89·6) | .. | 63·4% (51·6–73·8) | 91·0% (84·3–95·1) |
| Roe3 | 79·6% (67·1–88·2) | .. | 62·9% (51·0–73·3) | 90·2% (83·4–94·5) |
| Sweeney3 | 88·9% (77·8–94·8) | .. | 65·4% (54·0–75·3) | 94·4% (88·4–97·4) |
| At minimum sensitivity for a confirmatory test | ||||
| BATF2 | 65% | 85·8% (78·7–90·8) | 66·1% (52·7–77·4) | 85·2% (78·0–90·3) |
| Kaforou25 | .. | 92·1% (86·1–95·7) | 77·8% (63·8–87·5) | 86·1% (79·3–90·9) |
| Roe3 | .. | 92·1% (86·1–95·7) | 77·8% (63·8–87·5) | 86·1% (79·3–90·9) |
| Sweeney3 | .. | 93·7% (88·1–96·8) | 81·4% (67·4–90·3) | 86·3% (79·6–91·1) |
| At minimum specificity for a confirmatory test | ||||
| BATF2 | 53·7% (40·6–66·3) | 98% | 91·9% (77·3–97·4) | 83·3% (76·5–88·4) |
| Kaforou25 | 31·5% (20·7–44·7) | .. | 87·0% (66·0–95·8) | 77·1% (70·0–82·9) |
| Roe3 | 33·3% (22·2–46·6) | .. | 87·6% (67·4–96·1) | 77·6% (70·5–83·3) |
| Sweeney3 | 44·4% (32–57·6) | .. | 90·4% (73·7–97·0) | 80·6% (73·6–86·0) |
Data are % (95% CI). WHO defines target product profile criteria for a tuberculosis triage test as minimum 90% sensitivity and 70% specificity, optimum 95% sensitivity and 80% specificity, and for a confirmatory test as minimum 98% specificity and 65% sensitivity. PPV=positive predictive value. NPV=negative predictive value.